Home › Age, Renal Impairment and Depth of Response Analyses of the FirstTM...
 

Keywords :   


Age, Renal Impairment and Depth of Response Analyses of the FirstTM...

2014-12-08 04:49:40| Biotech - Topix.net

Celgene Corporation today announced that results were presented from multiple post-hoc analyses of its pivotal phase III FIRSTTM trial, comparing continuous REVLIMIDA plus low-dose dexamethasone to a fixed duration of 18 cycles of Rd or 12 cycles of melphalan, prednisone and thalidomide for the treatment of newly diagnosed, transplant-ineligible multiple myeloma. The studies were presented during the 56th American Society of Hematology annual meeting.

Tags: the age response depth

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.04Tesla China rival BYD sees profits and sales fall
30.04Thousands stranded as Australian airline weighs its future
30.04Migrants hit by high fees to send money home
30.04Physical checks to begin on EU-UK food and farm imports
29.04K-State researcher awarded $2.6 million to fight African swine fever
29.04Chairman Reinold Geiger Makes Offer To Take L\'Occitane Private
29.04FTC Fines Razer Over Misrepresented N95 Claims
29.04U by Kotex, Thinx and Walgreens Work to Fight Period Poverty
More »